1. Zambrano LD, Ellington S, Strid P, et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status – United States, January 22 – October 3, 2020. MMWR Morb Mortal Wkly Rep 202069:1641–1647.
2. DeSisto CL, Wallace B, Simeone RM, et al. Risk for stillbirth among women with and without COVID-19 at delivery hospitalization – United States, March 2020 – September 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1640–1645.
3. Butt AA, Chemaitelly H, Al Khal A, et al. SARS-CoV-2 vaccine effectiveness in preventing confirmed infection in pregnant women. J Clin Invest 2021131 (23):e153662–e153662.
4. Dagan N, Barda N, Biron-Shental T, et al. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. Nat Med 2021; 27:1693–1695
5. Lipkind HS, Vazquez-Benitez G, DeSilva M, et al. Receipt of COVID-19 vaccine during pregnancy and preterm or small-for-gestational-age at birth – eight integrated health care organizations, United States, December 15, 2020 – July 22, 2021. MMWR Morb Mortal Wkly Rep 202271:26–30.
6. Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary findings of Covid-19 vaccine safety mRNA in pregnant persons. N Engl J Med 2021384:2273–2282.
7. Zauche LH, Wallace B, Smoots AN, et al. Receipt of Covid-19 mRNA vaccines and risk of spontaneous abortion. N Engl J Med 2021385:1533–1535.
8. Magnus MC, Gjessing HK, Eide HN, Wilcox AJ, Fell DB, Håberg SE. Covid-19 Vaccination during pregnancy and first-trimester miscarriage. N Engl J Med 2021385:2008–2010.
9. Centers for Disease Control and Prevention. COVID-19 vaccines while pregnant or breastfeeding (https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html).
10. Abu Raya B, Edwards KM, Scheifele DW, Halperin SA. Pertussis and influenza immunization during pregnancy: a landscape review. Lancet Infect Dis 201717 (7):e209–e222.
11. Azziz-Baumgartner E, Grohskopf L, Patel M. Realizing the potential of maternal influenza vaccination. JAMA 2021; 325:2257–2259.
12. Omer SB. Maternal immunization. N Engl J Med 2017376:1256–1267.
13. Halasa NB, Olson SM, Staat MA, et al. Effectiveness of maternal vaccination with COVID-19 mRNA vaccine during pregnancy against COVID-19-associated hospitalization in infants aged <6 months - 17 states, July 2021 – January 2022. MMWR Morb Mortal Wkly Rep 202271:264–270.
14. Carlsen EØ, Magnus MC, Oakley L, et al. Association of COVID-19 vaccination during pregnancy with incidence of SARS-CoV-2 infection in infants. JAMA Intern Med 2022 June 1 (Epub ahead of print).
15. Mithal LB, Otero S, Shanes ED, Goldstein JA, Miller ES. Cord blood antibodies following maternal coronavirus disease 2019 vaccination during pregnancy. Am J Obstet Gynecol 2021; 225:192–194.
16. Beharier O, Plitman Mayo R, Raz T, et al. Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine. J Clin Invest 2021131:150319–150319.
17. Prabhu M, Murphy EA, Sukhu AC, et al. Antibody response to coronavirus disease 2019 (COVID-19) messenger RNA vaccination in pregnant women and transplacental passage into cord blood. Obstet Gynecol 2021138:278–280.
18. Perl SH, Uzan-Yulzari A, Klainer H, et al. SARS-CoV-2-specific antibodies in breast milk after COVID-19 vaccination of breastfeeding women. JAMA 2021325:2013–2014.
19. Baird JK, Jensen SM, Urban WJ, Fox BA, Baird JR. SARS-CoV-2 antibodies detected in mother’s milk post-vaccination. J Hum Lact 2021; 37:492–498.
20. Yang YJ, Murphy EA, Singh S, et al. Association of gestational age at coronavirus disease 2019 (COVID-19) vaccination, history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and a vaccine booster dose with maternal and umbilical cord antibody levels at delivery. Obstet Gynecol 2022139:373–380.
21. Trostle ME, Aguero-Rosenfeld ME, Roman AS, Lighter JL. High antibody levels in cord blood from pregnant women vaccinated against COVID-19. Am J Obstet Gynecol MFM 2021; 3:100481–100481.
22. Nir O, Schwartz A, Toussia-Cohen S, et al. Maternal-neonatal transfer of SARS-CoV-2 immunoglobulin G antibodies among parturient women treated with BNT162b2 messenger RNA vaccine during pregnancy. Am J Obstet Gynecol MFM 2022; 4:100492–100492.
23. Shook LL, Atyeo CG, Yonker LM, et al. Durability of anti-spike antibodies in infants after maternal COVID-19 vaccination or natural infection. JAMA 2022327:1087–1089.
24. Marks KJ, Whitaker M, Agathis NT, et al. Hospitalization of infants and children aged 0-4 years with laboratory-confirmed COVID-19 – COVID-NET, 14 states, March 2020 – February 2022. MMWR Morb Mortal Wkly Rep 202271:429–436.
25. Hobbs CV, Woodworth K, Young CC, et al. Frequency, characteristics and complications of COVID-19 in hospitalized infants. Pediatr Infect Dis J 202241 (3):e81–e86.
26. Mølgaard-Nielsen D, Fischer TK, Krause TG, Hviid A. Effectiveness of maternal immunization with trivalent inactivated influenza vaccine in pregnant women and their infants. J Intern Med 2019286:469–480.
27. Olson SM, Newhams MM, Halasa NB, et al. Vaccine effectiveness against life-threatening influenza illness in US Children. Clin Infect Dis 2022 January 13 (Epub ahead of print).
28. Chua H, Feng S, Lewnard JA, et al. The use of test-negative controls to monitor vaccine effectiveness: a systematic review of methodology. Epidemiology 2020; 31:43–64.
29. Olson SM, Newhams MM, Halasa NB, et al. Effectiveness of BNT162b2 vaccine against Critical Covid-19 in adolescents. N Engl J Med 2022386:713–723.
30. Olson SM, Newhams MM, Halasa NB, et al. Effectiveness of Pfizer-BioNTech mRNA vaccination against COVID-19 hospitalization among persons aged 12-18 years – United States, June – September 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1483–1488.
31. Office of the Federal Register. Code of federal regulations: a point in time eCFR system. Title 45 (https://www.ecfr.gov/cgi-bin/text-idx?SID=fc043bd2812f0775fa80066558a6bbcf&mc=true&node=pt45.1.46&rgn=div5#se45.1.46_1102).
32. Razzaghi H, Meghani M, Pingali C, et al. COVID-19 vaccination coverage among pregnant women during pregnancy – eight integrated health care organizations, United States, December 14, 2020 – May 8, 2021. MMWR Morb Mortal Wkly Rep 2021; 70:895–899.
33. Patel MK, Bergeri I, Bresee JS, et al. Evaluation of post-introduction COVID-19 vaccine effectiveness: summary of interim guidance of the World Health Organization. Vaccines 202139:4013–4024.
34. Centers for Disease Control and Prevention. COVID data tracker: variant proportions (https://covid.cdc.gov/covid-data-tracker/#variant-proportions).
35. Gray KJ, Bordt EA, Atyeo C, et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol 2021225 (3):303.e1–303.e17.
36. Klein NP, Stockwell MS, Demarco M, et al. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5-17 years – VISION Network, 10 States, April 2021 – January 2022. MMWR Morb Mortal Wkly Rep 202271:352–358.
37. Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of mRNA vaccines against, Covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: a prospective observational study. BMJ 2022376:e069761–e069761.
38. Centers for Disease Control and Prevention. Archived cumulative data: percent of pregnant people aged 18-49 years receiving at least one dose of a COVID-19 vaccine during pregnancy overall, by race / ethnicity, and date reported to CDC-Vaccine Safety Datalink *, United States | December 20, 2020 – January 20, 2022 (https://data.cdc.gov/Vaccinations/Cumulative-Data-Percent-of-Pregnant-People-aged-18/4ht3-nbmd/data).
39. Nemet I, Click L, Lustig Y, et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 omicron infection. N Engl J Med 2022386:492–494.
40. Thompson MG, Natarajan K, Irving SA, et al. Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance – VISION Network, 10 States, August 2021 – January 2022. MMWR Morb Mortal Wkly Rep 202271:139–145.